^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

Published date:
10/04/2013
Excerpt:
Acquired resistance to vemurafenib associated with reactivation of MAPK signaling as observed by elevated ERK1/2 phosphorylation levels in progressive lesions and the appearance of secondary NRAS(Q61) mutations or MEK1(Q56P) or MEK1(E203K) mutations.
DOI:
10.1200/JCO.2012.44.7888
Evidence Level:
Resistant: D – Preclinical
New
Title:

MEK1 mutations confer resistance to MEK and B-RAF inhibition

Excerpt:
Both MEK1(P124L) and MEK1(Q56P), which disrupts helix A, conferred cross-resistance to PLX4720, a selective B-RAF inhibitor in A375 cells.
DOI:
10.1073/pnas.0905833106